The study and its comparison
VINTAGE MI randomized 153 people after a first ST-elevation myocardial infarction to arginine or placebo alongside standard treatment. Follow-up was planned for six months, with cardiac function and vascular stiffness assessed. [1]
Neither measure improved significantly. Six deaths occurred among arginine recipients and none among controls, prompting the safety committee to close enrollment. [1]
What the finding establishes
The trial was relatively small, but the mortality imbalance cannot be omitted from a benefit discussion. It concerns a recent-heart-attack population rather than every healthy supplement user. Funding and conflicts were not established from the abstract. The study did not test taurine with arginine, and a nitric-oxide rationale provides no assurance that the combination is appropriate after an infarction. [1]
A hypothetical distinction
Imagine a supplement has a plausible vascular action but a trial finds no functional benefit and a mortality concern. Clinical outcomes take priority.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.